

## REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH SCHIZOPHRENIA

1. **Clinical practice guidelines. Treatment of schizophrenia.** *Canadian journal of psychiatry Revue canadienne de psychiatrie* 2005, **50**(13 Suppl 1):7s-57s.
2. AA Pharma Inc: **Fluphenazine.** In: *CA Product Monograph.* Vaughan , ON; 2012.
3. AA Pharma Inc: **Perphenazine.** In: *CA Product Monograph.* Vaughan, ON; 2012.
4. AA Pharma Inc: **Trifluoperazine.** In: *CA Product Monograph.* Vaughan, ON; 2014.
5. AA Pharma Inc: **ORAP (pimozide).** In: *CA Product Monograph.* Vaughan, ON; 2015.
6. Adams CE, Bergman H, Irving CB, Lawrie S: **Haloperidol versus placebo for schizophrenia.** *The Cochrane database of systematic reviews* 2013(11):CD003082.
7. Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K: **Chlorpromazine versus placebo for schizophrenia.** *The Cochrane database of systematic reviews* 2014(1):CD000284.
8. Alenius M, Wadelius M, Dahl ML, Hartvig P, Lindstrom L, Hammarlund-Udenaes M: **Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.** *J Psychiatr Res* 2008, **42**(11):884-893.
9. Allergan USA Inc: **Saphris (asenapine).** In: *US Product Monograph.* Irvine, CA; 2017.
10. Apotex Inc: **Apo-Methoprazine (methotrimeprazine maleate).** In: *CA Product Monograph.* Toronto, ON; 2012.
11. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S: **Clozapine versus other atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2010(11):CD006633.
12. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S: **Quetiapine versus other atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2013(11):CD006625.
13. AstraZeneca Canada Inc: **Seroquel (quetiapine fumarate).** In: *CA Product Monograph.* Mississauga, ON; 2015.
14. AstraZeneca Pharmaceuticals LP: **Seroquel (quetiapine).** In: *US Product Monograph.* Wilmington, DE; 2017.
15. AstraZeneca Pharmaceuticals LP: **Seroquel XR (quetiapine fumarate).** In: *US Product Monograph.* Wilmington, DE; 2018.
16. Azuma J, Hasunuma T, Kubo M, Miyatake M, Koue T, Higashi K, Fujiwara T, Kitahara S, Katano T, Hara S: **The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6**

- genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.** *European journal of clinical pharmacology* 2012, **68**(1):29-37.
17. Bakker PR, van Harten PN, van Os J: **Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.** *Molecular psychiatry* 2008, **13**(5):544-556.
  18. Barbui C, Signoretti A, Mule S, Boso M, Cipriani A: **Does the addition of a second antipsychotic drug improve clozapine treatment?** *Schizophrenia bulletin* 2009, **35**(2):458-468.
  19. Belgamwar RB, El-Sayeh HG: **Aripiprazole versus placebo for schizophrenia.** *The Cochrane database of systematic reviews* 2011(8):CD006622.
  20. Bhattacharjee J, El-Sayeh HG: **Aripiprazole versus typical antipsychotic drugs for schizophrenia.** *The Cochrane database of systematic reviews* 2008(3):CD006617.
  21. Bork JA, Rogers T, Wedlund PJ, de Leon J: **A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.** *The Journal of clinical psychiatry* 1999, **60**(7):469-476.
  22. Bristol-Myers Squibb Canada: **Modecate (fluphenazine decanoate).** In: *CA Product Monograph.* Montreal, QC; 2013.
  23. Bristol-Myers Squibb Canada: **Abilify (aripiprazole).** In: *CA Product Monograph.* Montreal, QC; 2015.
  24. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, Roots I: **The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.** *Clinical pharmacology and therapeutics* 2002, **72**(4):438-452.
  25. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR *et al*: **The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.** *Schizophrenia bulletin* 2010, **36**(1):71-93.
  26. Bushu Pharmaceutical Ltd: **Latuda (lurasidone).** In: *US Product Monograph.* Marlborough, MA; 2010.
  27. Cabaleiro T, Lopez-Rodriguez R, Ochoa D, Roman M, Novalbos J, Abad-Santos F: **Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.** *Human psychopharmacology* 2013, **28**(3):205-214.
  28. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA: **Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.** *Pharmacogenetics and genomics* 2009, **19**(5):373-382.
  29. Canadian Pharmacists Association: **Loxapine [CPhA monograph].** In: *RxTx.* Ottawa (ON); 2013.
  30. Canadian Pharmacists Association: **Phenothiazines [CPhA monograph].** In: *RxTx.* Ottawa, ON; 2015.
  31. Canadian Pharmacists Association: **Haloperidol [CPhA monograph].** In: *RxTx.* Ottawa, ON; 2016.

32. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B: **Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.** *The American journal of psychiatry* 2001, **158**(4):518-526.
33. Chakrabarti A, Bagnall A, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J: **Loxapine for schizophrenia.** *The Cochrane database of systematic reviews* 2007(4):CD001943.
34. Cho HY, Lee YB: **Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.** *Archives of pharmacal research* 2006, **29**(6):525-533.
35. Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS, Abreu RL, Oliveira GG, Vicente AM: **Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.** *The pharmacogenomics journal* 2010, **10**(5):418-430.
36. Coutinho E, Fenton M, Quraishi S: **Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses.** *The Cochrane database of systematic reviews* 2000(2):CD001164.
37. Cupp M: **Comparison of atypical antipsychotics.** In: *Pharmacist's Letter/Prescriber's Letter.* Stockton, CA; 2016.
38. Czerwensky F, Leucht S, Steimer W: **MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?** *The international journal of neuropsychopharmacology* 2013, **16**(9):2103-2109.
39. Davis JM, Chen N: **The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials.** *The Journal of clinical psychiatry* 2001, **62**(10):757-771.
40. Davis JM, Chen N, Glick ID: **A meta-analysis of the efficacy of second-generation antipsychotics.** *Archives of general psychiatry* 2003, **60**(6):553-564.
41. de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ: **Polymorphic variations in GSTM1, GSTT1, Pgp, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.** *Journal of clinical psychopharmacology* 2005, **25**(5):448-456.
42. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ: **The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.** *The Journal of clinical psychiatry* 2005, **66**(1):15-27.
43. de Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ: **A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.** *Pharmacopsychiatry* 2007, **40**(3):93-102.
44. Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y, Desta Z, Flockhart DA: **Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6.** *The pharmacogenomics journal* 2003, **3**(2):105-113.

45. Dinesh M, David A, Quraishi SN: **Depot pipotiazine palmitate and undecylenate for schizophrenia.** *The Cochrane database of systematic reviews* 2004(4):CD001720.
46. Dixon LB, Lehman AF, Levine J: **Conventional antipsychotic medications for schizophrenia.** *Schizophrenia bulletin* 1995, **21**(4):567-577.
47. Dold M, Samara MT, Li C, Tardy M, Leucht S: **Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.** *The Cochrane database of systematic reviews* 2015, **1**:CD009831.
48. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S: **Olanzapine for schizophrenia.** *The Cochrane database of systematic reviews* 2005(2):CD001359.
49. Eli Lilly and Company: **Zyprexa (olanzapine).** In: *US Product Monograph.* Indianapolis , IN; 2018.
50. Eli Lilly Canada Inc: **Zyprexa (olanzapine).** In: *CA Product Monograph.* Toronto, Ontario; 2016.
51. Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S: **CYP2D6 polymorphisms and atypical antipsychotic weight gain.** *Psychiatric genetics* 2002, **12**(1):55-58.
52. Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, Holman TL, Miller D: **Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.** *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 2005, **134B**(1):76-78.
53. Essali A, Al-Haj Haasan N, Li C, Rathbone J: **Clozapine versus typical neuroleptic medication for schizophrenia.** *The Cochrane database of systematic reviews* 2009(1):CD000059.
54. Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Moller HJ: **World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.** *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2005, **6**(3):132-191.
55. Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH *et al.*: **Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.** *The British journal of psychiatry : the journal of mental science* 2014, **205**(2):135-144.
56. Gardner DM, Baldessarini RJ, Waraich P: **Modern antipsychotic drugs: a critical overview.** *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne* 2005, **172**(13):1703-1711.
57. Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, Olajossy M, Marmurowska-Michalowska H, Limon J, Landowski J: **Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.** *The pharmacogenomics journal* 2009, **9**(4):234-241.
58. Haddad PM, Sharma SG: **Adverse effects of atypical antipsychotics : differential risk and clinical implications.** *CNS Drugs* 2007, **21**(11):911-936.

59. Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS: **Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.** *Annals of internal medicine* 2012, **157**(7):498-511.
60. Hartung B, Sampson S, Leucht S: **Perphenazine for schizophrenia.** *The Cochrane database of systematic reviews* 2015(3):CD003443.
61. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Møller HJ: **World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.** *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2012, **13**(5):318-378.
62. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Møller HJ: **World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.** *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry* 2013, **14**(1):2-44.
63. Hendset M, Hermann M, Lunde H, Refsum H, Molden E: **Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.** *European journal of clinical pharmacology* 2007, **63**(12):1147-1151.
64. Hendset M, Molden E, Knape M, Hermann M: **Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.** *Therapeutic drug monitoring* 2014, **36**(1):80-85.
65. HLS Therapeutics Inc: **Clozaril (clozapine).** In: *CA Product Monograph.* Etobicoke, ON; 2016.
66. HLS Therapeutics Inc: **Clozaril (clozapine).** In: *US Product Monograph.* Rosemont, PA; 2018.
67. Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, Conley RR, Poole Hoffmann V, Fijal BA: **Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.** *The Journal of clinical psychiatry* 2012, **73**(8):1077-1086.
68. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F: **Risperidone versus typical antipsychotic medication for schizophrenia.** *The Cochrane database of systematic reviews* 2003(2):CD000440.
69. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, O'Donovan MC, Nakamura J, Ozaki N, Iwata N: **Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.** *Pharmacogenomics* 2008, **9**(10):1437-1443.
70. Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G: **Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.** *Psychiatric genetics* 2003, **13**(3):163-168.
71. Janssen Inc: **Risperdal (risperidone oral).** In: *CA Product Monograph.* Toronto, ON; 2014.

72. Janssen Inc: **Invega Sustenna (paliperidone palmitate injectable)**. In: *CA Product Monograph*. Toronto, ON; 2015.
73. Janssen Inc: **Risperdal Consta (risperidone IM injection)**. In: *CA Product Monograph*. Toronto, ON; 2015.
74. Janssen Inc: **Invega (paliperidone extended release)**. In: *CA Product Monograph*. Toronto, ON; 2016.
75. Janssen Pharmaceuticals Inc: **Haldol Deconoate (haloperidol)**. In: *US Product Monograph*. Titusville, NJ; 2017.
76. Janssen Pharmaceuticals Inc: **Risperdal Consta (risperidone IM injection)**. In: *US Product Monograph*. Titusville, NJ; 2018.
77. Janssen Pharmaceuticals Inc: **Risperdal (risperidone oral)**. In: *US Product Monograph*. Titusville, NJ; 2018.
78. Janssen Pharmaceuticals Inc: **Invega (paliperidone extended release)**. In: *US Product Monograph*. Titusville, NJ; 2018.
79. Janssen Pharmaceuticals Inc: **Invega Trinza (paliperidone injectable)**. In: *US Product Monograph*. Titusville, NJ; 2019.
80. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: **Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUTLASS 1)**. *Archives of general psychiatry* 2006, **63**(10):1079-1087.
81. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J *et al*: **Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial**. *Lancet (London, England)* 2008, **371**(9618):1085-1097.
82. Kakahara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J: **Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6**. *International clinical psychopharmacology* 2005, **20**(2):71-78.
83. Kane JM, Leucht S, Carpenter D, Docherty JP: **The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary**. *The Journal of clinical psychiatry* 2003, **64** Suppl 12:5-19.
84. Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J: **A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment**. *The Journal of clinical psychiatry* 2011, **72**(3):349-355.



85. Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Hirayasu Y: **Delirium resolving upon switching from risperidone to quetiapine: implication of CYP2D6 genotype.** *Psychosomatics* 2005, **46**(4):374-375.
86. Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J: **Aripiprazole versus other atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2014(1):CD006569.
87. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU: **Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics.** *Molecular psychiatry* 2013, **18**(1):53-66.
88. Koch K, Mansi K, Haynes E, Adams CE, Sampson S, Furtado VA: **Trifluoperazine versus placebo for schizophrenia.** *The Cochrane database of systematic reviews* 2014(1):CD010226.
89. Kohnke MD, Griese EU, Stosser D, Gaertner I, Barth G: **Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.** *Pharmacopsychiatry* 2002, **35**(3):116-118.
90. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S: **Ziprasidone versus other atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2009(4):CD006627.
91. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmidt F, Lewis R, Kissling W, Leucht S: **Sertindole versus other atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2009(2):CD006752.
92. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, Kissling W, Leucht S: **Aripiprazole versus other atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2009(4):CD006569.
93. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S: **Olanzapine versus other atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2010(3):CD006654.
94. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, Kissling W, Leucht S: **Quetiapine versus other atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2010(1):CD006625.
95. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S: **Risperidone versus other atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2011(1):CD006626.
96. Kubo M, Koue T, Maune H, Fukuda T, Azuma J: **Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.** *Drug metabolism and pharmacokinetics* 2007, **22**(5):358-366.
97. Kumar A, Strech D: **Zuclopenthixol dihydrochloride for schizophrenia.** *The Cochrane database of systematic reviews* 2005(4):CD005474.

98. Laika B, Leucht S, Heres S, Schneider H, Steimer W: **Pharmacogenetics and olanzapine treatment: CYP1A2\*1F and serotonergic polymorphisms influence therapeutic outcome.** *The pharmacogenomics journal* 2010, **10**(1):20-29.
99. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH: **Risperidone-related weight gain: genetic and nongenetic predictors.** *Journal of clinical psychopharmacology* 2006, **26**(2):128-134.
100. Lee M, Jensen B, Regier L: **Antipsychotics comparison chart.** In: *RxFiles* Saskatoon, SK: Saskatoon Health Region; 2016.
101. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J: **Practice guideline for the treatment of patients with schizophrenia, second edition.** *The American journal of psychiatry* 2004, **161**(2 Suppl):1-56.
102. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H, Woerner MG, Kane JM, Goldman D, Malhotra AK: **DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.** *The American journal of psychiatry* 2006, **163**(3):529-531.
103. Leucht C, Kitzmantel M, Chua L, Kane J, Leucht S: **Haloperidol versus chlorpromazine for schizophrenia.** *The Cochrane database of systematic reviews* 2008(1):CD004278.
104. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: **Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.** *Lancet (London, England)* 2009, **373**(9657):31-41.
105. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM: **A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.** *The American journal of psychiatry* 2009, **166**(2):152-163.
106. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD *et al*: **Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.** *The New England journal of medicine* 2005, **353**(12):1209-1223.
107. Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, Hugo N: **Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.** *European journal of clinical pharmacology* 2016, **72**(2):175-184.
108. **Clinical and Research Information on Drug-Induced Liver Injury**  
[\[https://www.ncbi.nlm.nih.gov/books/NBK547852\]](https://www.ncbi.nlm.nih.gov/books/NBK547852)
109. Llerena A, Berez R, Dorado P, de la Rubia A: **QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.** *Journal of psychopharmacology (Oxford, England)* 2004, **18**(2):189-193.



110. LLerena A, de la Rubia A, Berecz R, Dorado P: **Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.** *Pharmacopsychiatry* 2004, **37**(2):69-73.
111. Lopez-Rodriguez R, Cabaleiro T, Ochoa D, Roman M, Borobia AM, Carcas AJ, Ayuso C, Novalbos J, Abad-Santos F: **Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.** *Pharmacogenomics* 2013, **14**(10):1203-1214.
112. Lundbeck Canada Inc: **Clopixol (zuclopenthixol).** In: *CA Product Monograph.* Montréal, QC; 2014.
113. Lundbeck Canada Inc: **Fluanxol (flupentixol).** In: *CA Product Monograph.* St-Laurent, QC; 2016.
114. Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE: **Fluphenazine decanoate (depot) and enanthate for schizophrenia.** *The Cochrane database of systematic reviews* 2015(2):CD000307.
115. Mahapatra J, Quraishi SN, David A, Sampson S, Adams CE: **Flupentixol decanoate (depot) for schizophrenia or other similar psychotic disorders.** *The Cochrane database of systematic reviews* 2014(6):CD001470.
116. Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS *et al*: **Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.** *Archives of general psychiatry* 2012, **69**(9):904-912.
117. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR: **The Mount Sinai conference on the pharmacotherapy of schizophrenia.** *Schizophrenia bulletin* 2002, **28**(1):5-16.
118. Matar HE, Almerie MQ, Sampson S: **Fluphenazine (oral) versus placebo for schizophrenia.** *The Cochrane database of systematic reviews* 2013(7):CD006352.
119. McCormack J CB, Calissi P: **Dosage Adjustment in Renal Impairment.** In: *Therapeutics.* Ottawa, ON: Canadian Pharmacists Association; 2018.
120. McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM *et al*: **Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.** *Jama* 2014, **311**(19):1978-1987.
121. Meltzer HY, Cucchiario J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A: **Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.** *The American journal of psychiatry* 2011, **168**(9):957-967.
122. Merck Canada Inc.: **Saphris (asenapine).** In: *CA Product Monograph.* Saint-Laurent, QC; 2016.
123. Mihara K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagashima U, Otani K, Kaneko S, Inoue Y: **Effects of the CYP2D6\*10 allele on the steady-state plasma concentrations of haloperidol**

- and reduced haloperidol in Japanese patients with schizophrenia.** *Clinical pharmacology and therapeutics* 1999, **65**(3):291-294.
124. Mothi M, Sampson S: **Pimozide for schizophrenia or related psychoses.** *The Cochrane database of systematic reviews* 2013(11):CD001949.
125. Muench J, Hamer AM: **Adverse effects of antipsychotic medications.** *American family physician* 2010, **81**(5):617-622.
126. Mulder H, Franke B, van der-BEEK van der AA, Arends J, Wilmink FW, Scheffer H, Egberts AC: **The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.** *Journal of clinical psychopharmacology* 2007, **27**(4):338-343.
127. Mulder H, Cohen D, Scheffer H, Gispen-de Wied C, Arends J, Wilmink FW, Franke B, Egberts AC: **HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.** *Journal of clinical psychopharmacology* 2009, **29**(1):16-20.
128. Muller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N *et al*: **Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.** *The pharmacogenomics journal* 2012, **12**(2):156-164.
129. Mylan Pharmaceuticals Inc: **Trifluoperazine.** In: *US Product Monograph.* Morgantown, WV; 2015.
130. Mylan Pharmaceuticals Inc: **Fluphenazine.** In: *US Product Monograph.* Morgantown, WV; 2016.
131. Mylan Pharmaceuticals Inc: **Loxapine.** In: *US Product Monograph.* Morgantown, WV; 2017.
132. Mylan Pharmaceuticals Inc: **Perphenazine.** In: *US Product Monograph.* Morgantown, WV; 2018.
133. National Collaborating Centre for Mental Health: **National Institute for Health and Clinical Excellence: Guidance.** In: *Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update).* edn. Leicester (UK): British Psychological Society, National Collaborating Centre for Mental Health.; 2009.
134. National Institute for Health and Care Evidence: **Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. [NICE Guideline TAG43].** In.; 2002.
135. National Institute for Health and Clinical Excellence: **Psychosis and schizophrenia in adults: prevention and management [NICE Guideline CG178].** In: *Psychosis and Schizophrenia in Adults: Treatment and Management: Updated Edition 2014.* 2014.
136. Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, Shibata N, Arai H: **The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).** *Therapeutic drug monitoring* 2008, **30**(1):35-40.
137. Nurmi EL, Spilman SL, Whelan F, Scahill LL, Aman MG, McDougale CJ, Arnold LE, Handen B, Johnson C, Sukhodolsky DG *et al*: **Moderation of antipsychotic-induced weight gain by energy**

- balance gene variants in the RUPP autism network risperidone studies.** *Translational psychiatry* 2013, **3**:e274.
138. Nussbaum A, Stroup TS: **Paliperidone for schizophrenia.** *The Cochrane database of systematic reviews* 2008(2):CD006369.
139. Nussbaum AM, Stroup TS: **Paliperidone palmitate for schizophrenia.** *The Cochrane database of systematic reviews* 2012(6):CD008296.
140. Ohara K, Nagai M, Tani K, Nakamura Y, Ino A, Ohara K: **Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia.** *Psychiatry research* 1998, **81**(2):117-123.
141. Ohara K, Tanabu S, Yoshida K, Ishibashi K, Ikemoto K, Shibuya H: **Effects of smoking and cytochrome P450 2D6\*10 allele on the plasma haloperidol concentration/dose ratio.** *Progress in neuro-psychopharmacology & biological psychiatry* 2003, **27**(6):945-949.
142. Ohnuma T, Shibata N, Matsubara Y, Arai H: **Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6.** *British journal of clinical pharmacology* 2003, **56**(3):315-320.
143. Omori IM, Wang J: **Sulpiride versus placebo for schizophrenia.** *The Cochrane database of systematic reviews* 2009(2):CD007811.
144. Otsuka America Pharmaceutical Inc: **Abilify Maintena (aripiprazole depot).** In: *US Product Monograph.* Rockville, MD; 2013.
145. Otsuka America Pharmaceutical Inc: **Abilify (aripiprazole).** In: *US Product Monograph.* Rockville, MD; 2017.
146. Otsuka Canada Pharmaceutical Inc: **Abilify Maintena (aripiprazole depot).** In: *CA Product Monograph.* Saint-Laurent, QC; 2016.
147. Panagiotidis G, Arthur HW, Lindh JD, Dahl ML, Sjoqvist F: **Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.** *Therapeutic drug monitoring* 2007, **29**(4):417-422.
148. Park JY, Shon JH, Kim KA, Jung HJ, Shim JC, Yoon YR, Cha IJ, Shin JG: **Combined effects of itraconazole and CYP2D6\*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.** *Journal of clinical psychopharmacology* 2006, **26**(2):135-142.
149. Pendopharm Division of Pharmascience Inc: **Xylac (loxapine).** In: *CA Product Monograph.* Montreal, QC; 2012.
150. Pfizer Canada Inc: **Zeldox (ziprasidone).** In: *CA Product Monograph.* Kirkland, QC; 2016.

151. Potkin SG, Cohen M, Panagides J: **Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.** *The Journal of clinical psychiatry* 2007, **68**(10):1492-1500.
152. Quraishi S, David A: **Depot haloperidol decanoate for schizophrenia.** *The Cochrane database of systematic reviews* 2000(2):CD001361.
153. Rattehalli RD, Jayaram MB, Smith M: **Risperidone versus placebo for schizophrenia.** *The Cochrane database of systematic reviews* 2010(1):CD006918.
154. Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Muller-Arends A, Weber K, Zach J, Muller N, Moller HJ: **Risperidone plasma levels, clinical response and side-effects.** *European archives of psychiatry and clinical neuroscience* 2005, **255**(4):261-268.
155. Risselada AJ, Mulder H, Heerdink ER, Gonera RK, Egberts TCG: **Association between the HTR2C rs1414334 and ADRA2A 1291 C/G polymorphisms and lipid levels in obese patients.** In: *Genetic determinants for metabolic abnormalities.* edn.; 2012: 107.
156. Roerig Div of Pfizer Inc: **Geodon (ziprasidone).** In: *US Product Monograph.* New York, NY; 2018.
157. Rogers HL, Bhattaram A, Zineh I, Gobburu J, Mathis M, Laughren TP, Pacanowski M: **CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: basis for the U.S. Food and Drug Administration's new dosing recommendations.** *The Journal of clinical psychiatry* 2012, **73**(9):1187-1190.
158. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L: **Risperidone metabolism in relation to CYP2D6\*10 allele in Korean schizophrenic patients.** *European journal of clinical pharmacology* 2001, **57**(9):671-675.
159. Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML, Bertilsson L: **Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.** *British journal of clinical pharmacology* 2001, **52**(3):265-271.
160. Roke Y, van Harten PN, Franke B, Galesloot TE, Boot AM, Buitelaar JK: **The effect of the Taq1A variant in the dopamine D(2) receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.** *Pharmacogenetics and genomics* 2013, **23**(9):487-493.
161. Saha KB, Bo L, Zhao S, Xia J, Sampson S, Zaman RU: **Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.** *The Cochrane database of systematic reviews* 2016, **4**:CD010631.
162. Sampford JR, Sampson S, Li BG, Zhao S, Xia J, Furtado VA: **Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.** *The Cochrane database of systematic reviews* 2016, **7**:CD010832.
163. Sampson S, Hosalli P, Furtado VA, Davis JM: **Risperidone (depot) for schizophrenia.** *The Cochrane database of systematic reviews* 2016, **4**:CD004161.
164. Sandoz Canada Inc: **Haloperidol LA.** In: *CA Product Monograph.* Boucherville, QC; 2013.

165. sanofi-aventis Canada Inc: **Piportil L4 (pipotiazine palmitate)**. In: *CA Product Monograph*. Laval, QC; 2011.
166. Scordo MG, Spina E, Facciola G, Avenoso A, Johansson I, Dahl ML: **Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone**. *Psychopharmacology* 1999, **147**(3):300-305.
167. Scottish Intercollegiate Guidelines Network (SIGN): **Management of schizophrenia**. In. Edinburgh: SIGN; 2013.
168. Shen YC, Chen SF, Chen CH, Lin CC, Chen SJ, Chen YJ, Luu SU: **Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients**. *J Psychiatr Res* 2009, **43**(6):600-606.
169. Shen X, Xia J, Adams CE: **Flupenthixol versus placebo for schizophrenia**. *The Cochrane database of systematic reviews* 2012, **11**:CD009777.
170. Shimoda K, Morita S, Yokono A, Someya T, Hirokane G, Sunahara N, Takahashi S: **CYP2D6\*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients**. *Therapeutic drug monitoring* 2000, **22**(4):392-396.
171. Sivaraman P, Rattehalli RD, Jayaram MB: **Levomepromazine for schizophrenia**. *The Cochrane database of systematic reviews* 2010(10):CD007779.
172. Someya T, Suzuki Y, Shimoda K, Hirokane G, Morita S, Yokono A, Inoue Y, Takahashi S: **The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population**. *Psychiatry and clinical neurosciences* 1999, **53**(5):593-597.
173. Someya T, Shimoda K, Suzuki Y, Sato S, Kawashima Y, Hirokane G, Morita S, Yokono A, Takahashi S: **Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population**. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 2003, **28**(8):1501-1505.
174. Srisurapanont M, Maneeton B, Maneeton N: **Quetiapine for schizophrenia**. *The Cochrane database of systematic reviews* 2004(2):CD000967.
175. Sukasem C, Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Chamnanphon M, Chamkrachchangpada B, Sinrachatanant A, Limsila P: **Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders**. *Journal of clinical psychopharmacology* 2016, **36**(2):141-146.
176. Sunovion Pharmaceuticals Canada Inc: **Latuda (lurasidone HCl)**. In: *CA Product Monograph*. Mississauga, Ontario; 2016.
177. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N: **Quetiapine versus typical antipsychotic medications for schizophrenia**. *The Cochrane database of systematic reviews* 2013(5):CD007815.

178. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA: **What CATIE found: results from the schizophrenia trial.** *Psychiatric services (Washington, DC)* 2008, **59**(5):500-506.
179. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines.** *Clinical pharmacology and therapeutics* 2011, **89**(5):662-673.
180. Tandon R, Cucchiario J, Phillips D, Hernandez D, Mao Y, Pikalov A, Loebel A: **A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.** *Journal of psychopharmacology (Oxford, England)* 2016, **30**(1):69-77.
181. Tardy M, Dold M, Engel RR, Leucht S: **Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia.** *The Cochrane database of systematic reviews* 2014(9):CD009227.
182. Tardy M, Huhn M, Engel RR, Leucht S: **Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.** *The Cochrane database of systematic reviews* 2014(8):CD009230.
183. Tardy M, Huhn M, Kissling W, Engel RR, Leucht S: **Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.** *The Cochrane database of systematic reviews* 2014(7):CD009268.
184. Tardy M, Huhn M, Engel RR, Leucht S: **Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.** *The Cochrane database of systematic reviews* 2014(10):CD009369.
185. Tardy M, Dold M, Engel RR, Leucht S: **Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia.** *The Cochrane database of systematic reviews* 2014(7):CD009396.
186. Taylor DM, Smith L: **Augmentation of clozapine with a second antipsychotic--a meta-analysis of randomized, placebo-controlled studies.** *Acta psychiatrica Scandinavica* 2009, **119**(6):419-425.
187. Teva Canada Limited: **Chlorpromazine.** In: *CA Product Monograph.* Toronto, ON; 2012.
188. Teva Canada Limited: **Haloperidol.** In: *CA Product Monograph.* Toronto, ON; 2016.
189. Teva Select Brands: **Orap (pimozide).** In: *US Product Monograph.* Horsham, PA; 2018.
190. Thomas P, Srivastava V, Singh A, Mathur P, Nimgaonkar VL, Lerer B, Thelma BK, Deshpande SN: **Correlates of response to Olanzapine in a North Indian Schizophrenia sample.** *Psychiatry research* 2008, **161**(3):275-283.
191. Upsher-Smith Laboratories Inc: **Chlorpromazine.** In: *US Product Monograph.* Maple Grove, MN; 2017.



192. Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH *et al*: **Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.** *Journal of psychopharmacology (Oxford, England)* 2007, **21**(8):837-842.
193. Wang J, Omori IM, Fenton M, Soares B: **Sulpiride augmentation for schizophrenia.** *The Cochrane database of systematic reviews* 2010(1):CD008125.
194. West-Ward Pharmaceuticals Corp: **Fluphenazine Decanoate.** In: *US Product Monograph.* Eatontown, NJ; 2016.
195. Xing Q, Qian X, Li H, Wong S, Wu S, Feng G, Duan S, Xu M, Gao R, Qin W *et al*: **The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.** *The international journal of neuropsychopharmacology* 2007, **10**(5):631-637.
196. Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Tokinaga N, Inoue Y, Otani K, Kaneko S: **Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol.** *Schizophrenia research* 2001, **52**(1):139-142.
197. Yasui-Furukori N, Tsuchimine S, Saito M, Nakagami T, Sato Y, Kaneko S: **Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients.** *Progress in neuro-psychopharmacology & biological psychiatry* 2007, **31**(6):1230-1234.
198. Yasui-Furukori N, Saito M, Tsuchimine S, Nakagami T, Sato Y, Sugawara N, Kaneko S: **Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.** *Progress in neuro-psychopharmacology & biological psychiatry* 2008, **32**(6):1491-1495.
199. Zai CC, De Luca V, Hwang RW, Voineskos A, Muller DJ, Remington G, Kennedy JL: **Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients.** *Molecular psychiatry* 2007, **12**(9):794-795.
200. Zhang JP, Lencz T, Malhotra AK: **D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.** *The American journal of psychiatry* 2010, **167**(7):763-772.
201. Zhang JP, Lencz T, Zhang RX, Nitta M, Maayan L, John M, Robinson DG, Fleischhacker WW, Kahn RS, Ophoff RA *et al*: **Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis.** *Schizophrenia bulletin* 2016, **42**(6):1418-1437.